[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100260783":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":61,"collaborators":10,"id":64,"slug":10,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Calgary","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Postural Tachycardia Syndrome (POTS)",null,"Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol",[13,14],"Drug: Phenylephrine","Drug: Isoproterenol",{"label":16,"type":10,"description":17,"interventionNames":18},"Healthy (control) Subjects","Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Phenylephrine","incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg",[16,9],[26],"NeoSynephrine",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Isoproterenol","incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm",[16,9],[32],"Isuprel",[34],{"name":35,"affiliation":5,"role":36},"Satish R Raj, MD, MSCI","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","403-210-6152","autonomic.research@ucalgary.ca",{"name":43,"role":39,"phone":44,"phoneExt":10,"email":41},"Robert S Sheldon, MD, PhD","403-220-8191",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Calgary","Alberta","T2N 4Z6","Canada",{"type":53,"coordinates":54},"Point",[55,56],-114.08529,51.05011,{"lat":56,"lon":55},[59,60],{"name":35,"role":39,"phone":40,"phoneExt":10,"email":41},{"name":43,"role":39,"phone":44,"phoneExt":10,"email":41},{"type":36,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr. Satish Raj","Professor","100260783",false,"NCT02673996","POTS Adrenergic Ab (CIHR Aims #1&2)","The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)","Inclusion Criteria:\n\n* Patients who have been previously diagnosed with POTS\n* Control subjects (patients not diagnosed with POTS)\n* Age between 18 - 60 years\n* Males and Females (Give that \\>80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects)\n* Able and willing to provide consent\n\nExclusion Criteria:\n\n* Smokers\n* Overt cause for postural tachycardia, i.e., acute dehydration\n* Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing\n* Highly trained athletes\n* Subjects with somatization or severe anxiety symptoms will be excluded\n* Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent\n* Hypertension defined as supine resting BP\\>145\u002F95 mmHg off medications or needing antihypertensive medication\n* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule\n* Unable to give informed consent",true,"ALL","18 Years","60 Years",{"count":75,"type":76},125,"ESTIMATED","OBSERVATIONAL","Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.",[80],"Postural Tachycardia Syndrome",[82,83,84,85],"antibody","autoimmune","adrenergic","autonomic","2026-04-29",{"date":88,"type":89},"2026-05-05","ACTUAL",{"date":91,"type":89},"2016-01",{"date":93,"type":76},"2030-12-31",{"name":5,"class":6},1]